Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular...

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Hypertension and type 2 diabetes are significant risk factors for left ventricular hypertrophy (LVH).
• LVH is associated with increased cardiovascular morbidity and mortality.
• Effective antihypertensive therapy is crucial for managing LVH in this patient population.

Purpose of the Study:

• To compare the effects of barnidipine versus lercanidipine, both in addition to losartan, on echocardiographic parameters in hypertensive patients with type 2 diabetes and LVH.
• To assess the impact of these treatment regimens on cardiac structure and diastolic function.

Main Methods:

• A randomized controlled trial involving 144 patients with hypertension, type 2 diabetes, and LVH.
• Patients received either barnidipine (20 mg/day) or lercanidipine (20 mg/day) plus losartan (100 mg/day) for 6 months.
• Echocardiography was performed at baseline and after 6 months to evaluate cardiac parameters.

Main Results:

• Both treatment groups showed a reduction in blood pressure.
• Barnidipine + losartan led to a greater reduction in left ventricular mass index and interventricular septal thickness.
• Barnidipine + losartan significantly improved diastolic function, indicated by an increased E/A ratio and reduced isovolumetric relaxation time.

Conclusions:

• Barnidipine in combination with losartan offers superior benefits in improving echocardiographic parameters, including LVH and diastolic function, compared to lercanidipine with losartan.
• This suggests barnidipine may be a more effective agent for managing cardiac remodeling in hypertensive type 2 diabetics with LVH.